Showing results (41-50 of 91) with videos related to
Sort By:
Pageof 10
The New England Journal of Medicine|June 16, 1988
Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cellsM B Atkins, J W Mier, D R Parkinson, et al.Optics Express|August 6, 2009
Aperture-coupled MIM plasmonic ring resonators with sub-diffraction modal volumesZ Han, V Van, W N Herman, et al.Antisense Research and Development|January 1, 1991
Non-sequence-specific inhibition of transferrin receptor expression in HL-60 leukemia cells by phosphorothioate oligodeoxynucleotidesP T Ho, K Ishiguro, E Wickstrom, et al.Cancer Research|December 1, 1986
Inhibitory effects of elevated temperature on human cytokine production and natural killer activityC A Dinarello, R A Dempsey, M Allegretta, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1993
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomasJ H Edmonson, L M Ryan, R H Blum, et al.Optics Letters|September 10, 2009
Picosecond-pulse generation from a continuous-wave neodymium:phosphate glass laserL Yan, J D Ling, P T Ho, et al.Peptide Research|January 1, 1993
An improved low racemization solid-phase method for the synthesis of reduced dipeptide (psi CH2NH) bond isosteresP T Ho, D Chang, J W Zhong, et al.Cancer Research|September 1, 1990
Clonal analysis of lymphocytes from tumor, peripheral blood, and nontumorous kidney in primary renal cell carcinomaT Y Kim, A C von Eschenbach, M D Filaccio, et al.Blood|May 15, 1992
Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptorC F LeMaistre, C Meneghetti, M Rosenblum, et al.Clinical Pharmacology and Therapeutics|June 19, 1998
Cancer recurrences and secondary primary cancers after use of antihistamines or antidepressantsS R Weiss, B H McFarland, G A Burkhart, et al.Pageof 10